) has enrolled the first patient in a multi-center study
evaluating the efficiency of the NanoKnife System for ablation of
prostrate cancer. The clinical trial is being conducted by the
Clinical Research Office of the Endourological Society (CROES) at
the Academic Medical Center in Amsterdam.
ANGIODYNAMICS (ANGO): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
GIVEN IMAGING (GIVN): Get Free Report
LUMINEX CORP (LMNX): Free Stock Analysis
To read this article on Zacks.com click here.
"The Safety and Efficacy of Irreversible Electroporation (IRE)
for the Ablation of Prostate Cancer Assessed by Procedural
Related Side Effects and Post Prostatectomy Histology: A
Prospective Human In-Vivo Study" intends to evaluate the safety,
efficacy and patient satisfaction of AngioDynamics' flagship
NanoKnife offering in treating prostrate cancer. The study will
enroll 16 eligible patients who will be treated with the
NanoKnife System roughly a month before prostatectomy. On
successful completion of this study, CROES will conduct a second
study with 200 patients.
Researchers in the urology field have been increasingly analyzing
the effectiveness of focal ablation for the treatment of low-risk
prostrate cancer in a minimally invasive manner. We are
encouraged by AngioDynamics' efforts to invest in clinical trials
to analyze the potential of the NanoKnife System. The company has
invested $26.3 million on research & development (R&D) in
The N.Y.-based therapeutic and diagnostic devices maker is
conducting similar studies in the U.S. where institutes such as
the University of Miami have shown interest in conducting a study
on the NanoKnife upon approval from the Institutional Review
Board (IRB). Moreover, the U.S. FDA has also cleared an
Investigational Device Exemption (IDE) recently to begin a
clinical trial of the product for the ablation of focal prostate
cancer. The company plans to start patient enrollment in the
second quarter of fiscal 2014, which ends on Nov 30, 2013.
AngioDynamics should continue to benefit from the ongoing shift
from open surgery to less invasive interventional procedures.
Despite the near-term operational glitches, the company has the
ability to grow in the long term on the back of higher
international sales, new products, acquisitions, as well as
operational synergies from its cost saving measures.
ANGO has a Zacks Rank #3 (Hold). Medical stocks such as
) are worth considering. All these stocks have a Zacks Rank #2